BRPI0607140A2 - compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism - Google Patents
compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolismInfo
- Publication number
- BRPI0607140A2 BRPI0607140A2 BRPI0607140-6A BRPI0607140A BRPI0607140A2 BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2 BR PI0607140 A BRPI0607140 A BR PI0607140A BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- cells
- stimulating
- carbohydrate
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 150000001720 carbohydrates Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 2
- 230000023852 carbohydrate metabolic process Effects 0.000 title abstract 2
- 150000002596 lactones Chemical class 0.000 title abstract 2
- 230000037356 lipid metabolism Effects 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 210000001789 adipocyte Anatomy 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 230000003914 insulin secretion Effects 0.000 title 1
- 210000000663 muscle cell Anatomy 0.000 title 1
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical class C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 abstract 1
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 abstract 1
- 230000002473 insulinotropic effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
COMPOSTO, USO DO COMPOSTO E/OU USO DE UM SAL, LACTONA OU PRó-MEDICAMENTO FARMACEUTICAMENTE ACEITáVEL DO DITO COMPOSTO, COMPOSIçãO FARMACêUTICA, KIT FARMACêUTICO, MéTODO PARA ESTIMULAR A CAPTAçãO DE GLICOSE PELAS CéLULAS MUSCULARES E/OU CéLULAS DE ADIPóCITO, MéTODO PARA ESTIMULAR A SECREçãO DE INSULINA PELAS CéLULAS PANCREáTICAS CéLULAS-13 E MéTODO PARA O TRATAMENTO DE UM MAMìFERO QUE TEM UM DISTúRBIO DO METABOLISMO DE CARBOIDRATOS OU DE LIPìDIOS. A invenção refere-se aos isómeros configuracionais de 4-hidróxi isoleucina e às lactonas, sais farmaceuticamente aceitáveis e pró-medicamentos dos mesmos, aos processos para a sua preparação e às composições farmacêuticas que compreendem os mesmos. Os isómeros da invenção exibem atividade insulinotrópica e, desse modo, podem ser úteis para a prevenção e o tratamento dos distúrbios do metabolismo de carboidratos ou de lipídios, incluindo o diabetes meilitus (diabetes tipo 1 e tipo 2), pré-diabetes e a Síndrome Metabólica.COMPOUND, USE OF COMPOUND AND / OR USE OF A PHARMACEUTICALLY ACCEPTABLE SALT, LACTONA OR PRODUCT OF COMPOUND, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL KIT, METHOD FOR STIMULATING CELLULULAR CELLULLE OR CELLULLE CELLULATION PANCREATIC CELL-13 CELLS AND METHOD FOR THE TREATMENT OF A MAMMIFER THAT HAS A DISORDER OF CARBOHYDRATE OR LIPID METABOLISM. The invention relates to configurational isomers of 4-hydroxy isoleucine and to lactones, pharmaceutically acceptable salts and prodrugs thereof, processes for their preparation and pharmaceutical compositions comprising them. The isomers of the invention exhibit insulinotropic activity and thus may be useful for the prevention and treatment of carbohydrate or lipid metabolism disorders, including diabetes meilitus (type 1 and type 2 diabetes), prediabetes, and the syndrome. Metabolic
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65441305P | 2005-02-18 | 2005-02-18 | |
| PCT/IB2006/001758 WO2006117696A2 (en) | 2005-02-18 | 2006-02-17 | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607140A2 true BRPI0607140A2 (en) | 2009-08-11 |
Family
ID=37086084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607140-6A BRPI0607140A2 (en) | 2005-02-18 | 2006-02-17 | compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1853552A2 (en) |
| JP (1) | JP2008530198A (en) |
| CN (1) | CN101128418A (en) |
| AU (1) | AU2006242851A1 (en) |
| BR (1) | BRPI0607140A2 (en) |
| CA (1) | CA2598491A1 (en) |
| MX (1) | MX2007009985A (en) |
| WO (1) | WO2006117696A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538211A (en) * | 2005-03-22 | 2008-10-16 | イノディア インク． | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| WO2008154743A1 (en) * | 2007-06-19 | 2008-12-24 | Innodia Inc. | Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof |
| WO2009085180A1 (en) * | 2007-12-20 | 2009-07-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
| AU2016342027B2 (en) * | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| TWI776886B (en) | 2017-04-26 | 2022-09-11 | 美商奈維特製藥公司 | Modulators of sestrin-gator2 interaction and uses thereof |
| JP7644002B2 (en) | 2018-10-24 | 2025-03-11 | ナビター ファーマシューティカルズ， インコーポレイテッド | Polymorphic Compounds and Uses Thereof |
| EP4051259A4 (en) | 2019-11-01 | 2023-11-22 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
| CN112089710B (en) * | 2020-08-07 | 2022-04-01 | 郑州大学 | Application of 4-hydroxyisoleucine in preparation of antitumor drugs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797767B1 (en) * | 1999-08-27 | 2002-06-14 | Centre Nat Rech Scient | USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF INSULIN RESISTANCES |
| CN1921881A (en) * | 2003-10-27 | 2007-02-28 | 因诺迪亚公司 | Use of hydroxylated amino acids for treating diabetes |
| EP1657236A1 (en) * | 2004-11-10 | 2006-05-17 | Centre National De La Recherche Scientifique (Cnrs) | Method for preparing diastereoisomers of 4-hydroxy isoleucine |
-
2006
- 2006-02-17 BR BRPI0607140-6A patent/BRPI0607140A2/en not_active Application Discontinuation
- 2006-02-17 CN CNA2006800050682A patent/CN101128418A/en active Pending
- 2006-02-17 AU AU2006242851A patent/AU2006242851A1/en not_active Abandoned
- 2006-02-17 JP JP2007555732A patent/JP2008530198A/en active Pending
- 2006-02-17 CA CA002598491A patent/CA2598491A1/en not_active Abandoned
- 2006-02-17 EP EP06765601A patent/EP1853552A2/en not_active Withdrawn
- 2006-02-17 MX MX2007009985A patent/MX2007009985A/en not_active Application Discontinuation
- 2006-02-17 WO PCT/IB2006/001758 patent/WO2006117696A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1853552A2 (en) | 2007-11-14 |
| CN101128418A (en) | 2008-02-20 |
| MX2007009985A (en) | 2008-03-11 |
| WO2006117696A3 (en) | 2007-01-25 |
| AU2006242851A1 (en) | 2006-11-09 |
| JP2008530198A (en) | 2008-08-07 |
| WO2006117696A2 (en) | 2006-11-09 |
| CA2598491A1 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201457B2 (en) | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | |
| Li et al. | Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice | |
| KR102396831B1 (en) | Compositions and methods for joint | |
| Li et al. | Gastrodin and isorhynchophylline synergistically inhibit MPP+-induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK-3β pathways: involvement of Nrf2 nuclear translocation | |
| ECSP088139A (en) | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDE | |
| UA100384C2 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
| BRPI0607156A2 (en) | compound, pharmaceutical composition, use of the compound, pharmaceutical kit, method for stimulating glucose uptake by muscle cells and / or adipocyte cell and method for stimulating pancreatic secretion | |
| BRPI0718596B8 (en) | pharmaceutical compositions for combination therapy with sglt-2 and metformin inhibitors | |
| BRPI1015120A2 (en) | lipid compound, pharmaceutical and lipid compositions, methods of producing lipid compound and for preventing or treating diseases and uses of at least one compound | |
| HRP20221106T1 (en) | Methods for the treatment of abnormal involuntary movement disorders | |
| BRPI0507189A (en) | combined use of a glp-1 agonist and gastrin compounds | |
| TWI488630B (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| BRPI0516454A (en) | compound, process for preparing a compound, pharmaceutical composition comprising it, its use, method for treating and prophylaxis of diseases, and type II diabetes | |
| BR112015001056A2 (en) | compound, pharmaceutical composition, methods for the treatment of aldosterone-mediated disorders, for the treatment of disease or a condition, for the treatment of metabolic syndrome, for the treatment of a physiological or pathological disease, and for the treatment of chronic kidney disease, insufficiency renal disease or diabetic nephropathy | |
| Rytting et al. | Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells | |
| MX2007009985A (en) | Diastereoisomers of 4-hydroxyisoleucine and uses thereof. | |
| Kulkarni et al. | Antidiabetic potential of Rourea minor (Gaertn.) root in streptozotocin—induced diabetic rats | |
| BRPI0611550A2 (en) | use of a compound selected from the group consisting of 4-hydroxy isoleucine isomers, 4-hydroxy isoleucine analogs, and lactones, salts, metabolites, solvates and / or pharmaceutically acceptable prodrugs of said isomers and analogs, compound, pharmaceutical kit , pharmaceutical composition, use of the compound and kit with compound | |
| Yousaf et al. | Hypolipidemic effect of extra virgin olive oil in diabetic rats | |
| US20230110065A1 (en) | Combination of anethole trithione or its derivative, 4-oh-anethole trithione, with doxycycline or minocycline for the use thereof in the treatment of parkinson's disease | |
| Marshall et al. | Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A Narrative Review. Nutrients 2022, 14, 529 | |
| Selvakumar et al. | Neurotoxicity associated with neuroleptic haloperidol induced tardive dyskinesia in Albino mice: Protective role of morin | |
| HK40079409A (en) | Compositions and methods for joint health | |
| EA200702274A1 (en) | HARD CRYSTALLINE AND AMORPHOUS FORMS (-) - HALOPHENATE AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD | |
| BR112022007623A2 (en) | COMPOSITIONS TO PREVENT OR TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |